Skip navigation

SPEAK OUT: Lewis A. Miller

As demonstrated at the September meeting of the National Task Force on CME Provider/Industry Collaboration, pharmaceutical companies are coming under almost microscopic scrutiny for their activities supporting accredited CME — not only from the Accreditation Council for CME and the Food and Drug Administration, but now also from the Office of Inspector General of the Department of Health and Human Services.

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.